THYM
Bovine thymus extract containing multiple thymic peptides including thymulin. Used in Russia for immune modulation.
Regulatory status (as of Sept 2026)
Not FDA-approved; not available as a US drug.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Thymalin is approved as a medicine in some countries outside the US, but not by the FDA. Bovine thymus extract containing multiple thymic peptides including thymulin.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Intramuscular injection |
| Research stage | Approved outside US |
| Dosing | Published research: No PubMed-indexed dosing study found detailsNo PubMed-indexed dosing study found; Russian clinical use (e.g., COVID-19 adjunct studies) does not report dose in abstracts.Community-reportedCommunity-reported: 10 mg daily, intramuscular injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is an extract of thymus gland peptides thought to support the immune system. Proposed mechanism: an immunomodulatory polypeptide extract of thymus. Its proposed actions include influencing the differentiation of human hematopoietic stem cells (Khavinson 2021) and, for its KE and EW dipeptide components, effects on gene expression in vitro (Linkova 2023).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported 10 mg daily (intramuscular injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Thymalin | No published PK data found | Intramuscular injection | Approved outside US |
| KPV | No published PK data found | Subcutaneous injection, Oral, Topical | Preclinical (animal) |
| LL-37 | Unknown | Subcutaneous injection | Phase 2 |
| Thymopoietin II Fragment (TP-1) | Unknown | Subcutaneous injection | Preclinical (animal) |
| Thymosin Alpha-1 | No published human PK data found; ~3 h for native Tα1 in rats (Shen 2019). Literature describes a 'short plasma half-life' requiring twice-weekly s.c. dosing. | Subcutaneous injection | Approved outside US |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Immune category. View All Immune Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.